Press Coverage

Hepatitis C Treatment: Study Finds No Liver, Kidney or Cardiovascular Adverse Effects

Interview mentions that an ISMP QuarterWatchTM report raising questions about whether direct acting antiviral medications for the treatment of Hepatitis C posed any significant safety risks for patients was the impetus for further study.

For the full text, visit MedicalResearch.com online.

More News

Since the 2021-2022 influenza (flu) vaccine became available in September, the Institute for Safe Medication Practices (ISMP) has received multiple reports of mix-ups. Some patients have consented to a flu vaccine but received one of the COVID-19 vaccines instead, while others have received the flue